Literature DB >> 9306205

Increase in immunoreactivity for endothelin-1 in blood vessels of rat liver metastases: experimental sarcoma and carcinoma.

A Loesch1, M Turmaine, M Loizidou, R Crowe, S Ashraf, I Taylor, G Burnstock.   

Abstract

Using electron immunocytochemistry, blood vessels in the normal rat liver and in 2 different animal models of liver metastases: (1) Hooded Lister rat with MC28 tumour, a sarcoma, and (2) nude rat with HT29 tumour, a carcinoma, were investigated for the presence of endothelin-1. In the normal livers, small subpopulations of vascular endothelial cells displayed discrete immunoreactivity for endothelin-1. In the livers with malignant tumours, there was a substantial increase in endothelin-1-immunoreactive endothelial cells in vessels located at the tumour periphery. In the controls, antibody to endothelin-1 also labelled sporadically some fibroblast/fibroblast-like cells associated with the blood vessels. In contrast, intense immunoreactivity for endothelin-1 was frequently associated with the tumour cells and/or fibroblast cells in both types of tumour examined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306205      PMCID: PMC1467681          DOI: 10.1046/j.1469-7580.1997.19120291.x

Source DB:  PubMed          Journal:  J Anat        ISSN: 0021-8782            Impact factor:   2.610


  29 in total

1.  Rapid release of endothelin and ATP from isolated aortic endothelial cells exposed to increased flow.

Authors:  P Milner; P Bodin; A Loesch; G Burnstock
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

2.  Production of endothelin in human cancer cell lines.

Authors:  M Kusuhara; K Yamaguchi; K Nagasaki; C Hayashi; A Suzaki; S Hori; S Handa; Y Nakamura; K Abe
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

3.  Localization of adrenergic and neuropeptide tyrosine-containing nerves in the mammalian liver.

Authors:  A D Burt; D Tiniakos; R N MacSween; M R Griffiths; E Wisse; J M Polak
Journal:  Hepatology       Date:  1989-06       Impact factor: 17.425

4.  Calcitonin gene-related peptide immunoreactivity in the biliary pathway and liver of the guinea-pig: distribution and colocalization with substance P.

Authors:  L E Goehler; C Sternini; N C Brecha
Journal:  Cell Tissue Res       Date:  1988-07       Impact factor: 5.249

Review 5.  Modification of tumour blood flow--a review.

Authors:  H I Peterson
Journal:  Int J Radiat Biol       Date:  1991 Jul-Aug       Impact factor: 2.694

6.  Endothelin is a potent mitogen for rat vascular smooth muscle cells.

Authors:  Y Hirata; Y Takagi; Y Fukuda; F Marumo
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

7.  Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Wilmott; J H McKillop; C S McArdle
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

8.  Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines.

Authors:  M Shichiri; Y Hirata; T Nakajima; K Ando; T Imai; M Yanagisawa; T Masaki; F Marumo
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

9.  Light and electron microscopy of neuropeptide Y-containing nerves in human liver, gallbladder, and pancreas.

Authors:  W G Ding; M Fujimura; A Mori; I Tooyama; H Kimura
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

10.  Facilitation by partial hepatectomy of tumor growth within the rat liver following intraportal injection of syngeneic tumor cells.

Authors:  M C Loizidou; R J Lawrance; S Holt; N J Carty; A J Cooper; P Alexander; I Taylor
Journal:  Clin Exp Metastasis       Date:  1991 Jul-Aug       Impact factor: 5.150

View more
  1 in total

1.  Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism.

Authors:  E Asham; A Shankar; M Loizidou; S Fredericks; K Miller; P B Boulos; G Burnstock; I Taylor
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.